阿德福韦治疗乙型肝炎肝硬化的疗效评价  

Clinical analysis of adefovir dipivoxil in treatment of hepatitis B cirrhosis

作　　者：王海舰[1] 梁艳丽[1] 梅存金 

机构地区：[1]徐州市传染病医院,江苏徐州221004

出　　处：《中国校医》2009年第6期669-670,共2页Chinese Journal of School Doctor

摘　　要：目的观察阿德福韦治疗乙型肝炎肝硬化的疗效和安全性。方法乙型肝炎肝硬化78例,其中对照组36例,给予护肝、支持等综合治疗;治疗组42例,在综合治疗的基础上,加服阿德福韦10 mg,每日1次,2组病例均在治疗12月后观察肝功能、HbeAg、HBV DNA、Child-Pugh评分等。结果治疗组患者血清生化学指标改善、HbeAg阴转、HBV DNA水平下降及Child—pugh分级评分与对照组相比,差异均有统计学意义。治疗组无不良反应发生。结论阿德福韦具有较强的抑制HBV DNA复制的作用,通过抑制体内的乙肝病毒复制,能使乙肝患者获得病毒学应答及肝脏生化指标改善,治疗乙型肝炎肝硬化疗效肯定,安全性良好。Objective To evaluate the efficacy and safety of adefovir dipivoxil （ADV） in the treatment of hepatitis B cirrhosis. Methods A total of 78 patients with hepatitis B cirrhosis were randomized into an ADV group or control group, and there were 42 patients in the ADV group and 36 patients in the control group. The patients in the control group received ordinary liver protective drugs while the patients in the ADV group received additional 10 mg of ADV once a day during 12 months. ALT, AST and HBV-DNA were assayed, and Child-Pugh scores were evaluated at the beginning and the end of the test, respectively. Results At the end of the test, the clearance rates of HBVDNA were52.38% （22/42） and 23.08% （6/26） in the ADV group and control group, respectively, and there was a significant difference,P〈0.01. The clearance rates of HBeAg were 16.67% （7/42） and 2.78% （1/36） in the ADV group and control group, respectively, and there was a significant difference, P 〈 0.05. The average Child-Pugh scores between the ADV group and control group had a significant difference, P〈 0.01. There were no obvious side effects in the ADV group. Conclusions Adefovir dipivoxil can reduce serum HBVDNA levels significantly, and normalize the levds of ALT and AST, and is of safety.

关 键 词：肝炎 乙型 肝硬化 阿德福韦 治疗结果 

分 类 号：R575[医药卫生—消化系统]